Sprint Bioscience AB (publ) and South Korean LG Chem Life Sciences Company have entered into a research collaboration and licence agreement for the research, development and commercialisation of Sprint Bioscience’s program in early development phase for the treatment of non-alcohol-induced fatty liver (NASH, nonalcoholic steatohepatitis) and metabolic diseases. According to the terms of the agreement, Sprint Bioscience will obtain around 2,5 million USD in access payments and research funding during the first twelve months. Sprint Bioscience is entitled to around 230 million USD in potential preclinical, clinical and net sales-based milestone payments. In addition, Sprint Bioscience is entitled to royalties on world-wide net sales of potential resulting products from the collaboration.
Cirio law firm has advised Sprint Bioscience in connection with the transaction through Anders Burén (Life Sciences).